Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 1
2016 1
2019 3
2020 1
2021 3
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ; MAIA Trial Investigators. Facon T, et al. N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249. N Engl J Med. 2019. PMID: 31141632 Free PMC article. Clinical Trial.
Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma.
Mithraprabhu S, Reynolds J, Turner R, Quach H, Horvath N, Kerridge I, Kalff A, Bergin K, Hocking J, Yuen F, Khong T, Durie BM, Spencer A. Mithraprabhu S, et al. Among authors: hocking j. Blood Cancer J. 2023 Feb 13;13(1):25. doi: 10.1038/s41408-023-00796-9. Blood Cancer J. 2023. PMID: 36781844 Free PMC article. No abstract available.
TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing.
Reale A, Khong T, Mithraprabhu S, Savvidou I, Hocking J, Bergin K, Ramachandran M, Chen M, Dammacco F, Ria R, Silvestris F, Vacca A, Reynolds J, Spencer A. Reale A, et al. Among authors: hocking j. Leuk Lymphoma. 2021 Feb;62(2):337-347. doi: 10.1080/10428194.2020.1832659. Epub 2020 Oct 31. Leuk Lymphoma. 2021. PMID: 33131357
Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction.
Boyle S, Wellard C, Moore EM, Blacklock H, Harrison SJ, Ho PJ, Hocking J, McQuilten ZK, Quach H, Spearing R, Wood EM, Spencer A, Mollee P; Myeloma and Related Diseases Registry investigators. Boyle S, et al. Among authors: hocking j. Eur J Haematol. 2021 Oct;107(4):497-499. doi: 10.1111/ejh.13677. Epub 2021 Jun 26. Eur J Haematol. 2021. PMID: 34129711 No abstract available.
11 results